Physician profile
Alvin Cacho
NPI 1205918497
$13,413.67
in general payments reported to CMS, 2019-2025
44 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,278 · 2020: $1,545 · 2021: $2,727 · 2022: $2,649 · 2023: $1,059 · 2024: $1,024 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,995 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,994.59 |
| Education | $220.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,439.90 | 2019-2025 | Brilinta, Farxiga |
| Novartis Pharmaceuticals Corporation | $1,224.52 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,152.95 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $1,123.88 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $998.48 | 2019-2024 | Watchman Flx |
| Amgen INC. | $741.71 | 2019-2025 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $588.62 | 2021-2025 | |
| Pfizer INC. | $571.09 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $427.79 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $413.10 | 2021-2024 | Verquvo |
| Esperion Therapeutics, INC. | $391.75 | 2020-2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $368.77 | 2019-2022 | |
| Shockwave Medical, INC | $363.99 | 2019-2025 | |
| Medtronic Vascular, INC. | $358.24 | 2019-2020 | |
| Astellas Pharma US INC | $335.90 | 2019-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alvin Cacho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.